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A multi-LU-domain-containing protein denoted C4.4A exhibits a tightly regulated membrane-associated expression in the
suprabasal layers of stratified squamous epithelia such as skin and the esophagus, and the expression of C4.4A is dysregulated
in various pathological conditions. However, the biological function of C4.4A remains unknown. To enable further studies, we
evaluated the expression of C4.4A in monolayer cultures of normal human keratinocytes and in tissue-engineered skin substitutes
(TESs) produced by the self-assembly approach, which allow the formation of a fully differentiated epidermis tissue. Results showed
that, in monolayer, C4.4A was highly expressed in the centre of keratinocyte colonies at cell-cell contacts areas, while some cells
located at the periphery presented little C4.4A expression. In TES, emergence of C4.4A expression coincided with the formation of
the stratum spinosum.After the creation of a woundwithin the TES, C4.4A expression was observed in the suprabasal keratinocytes
of the migrating epithelium, with the exception of the foremost leading keratinocytes, which were negative for C4.4A. Our results
are consistent with previous data in mouse embryogenesis and wound healing. Based on these findings, we conclude that this
human TES model provides an excellent surrogate for studies of C4.4A and Haldisin expressions in human stratified epithelia.
1. Introduction
The stratified squamous epithelium of human epidermis
represents a highly complex organ, which provides an impor-
tant protective barrier against opportunistic pathogens and
dehydration. Several proteins belonging to the Ly6/uPAR/𝛼-
neurotoxin (LU) protein domain family [1] are expressed by
epidermal keratinocytes, including E48, SLURP 1, C4.4A, and
Haldisin [2]. LU domain-containing proteins have evolved
to serve multiple diverse physiologic functions, for exam-
ple, inhibition of autologous complement activation, CD59
[3]; driving cell surface-associated plasminogen activation,
uPAR [4]; localizing intravascular triglyceride hydrolysis on
capillaries, GPIHBP1 [5, 6]; regulating fertility, TEX101 [7];
and neutrophil function, CD177 [8]. It is noteworthy that
maintenance of epidermal homeostasis is compromised by
missense mutations or congenital deficiency of one of the LU
proteins (SLURP1: secreted Ly6/uPAR protein 1), which leads
to hyperkeratosis and palmoplantar keratoderma—adisorder
known as Mal de Meleda [9, 10].
We have previously reported that two genes, LYPD3 and
LYPD5—located in the same small gene cluster as CD177,
TEX101, and PLAUR on chromosome 19q13 [11] and encoding
the LU proteins C4.4A and Haldisin—constitute a new set
of surface-exposed histological biomarkers for squamous
epithelia differentiation: C4.4A being confined to stratum
spinosum [12] and Haldisin to stratum granulosum [13]. Both
proteins are glycosyl-phosphatidyl-inositol- (GPI-) anchored
membrane glycoproteins with two LU domains [13–15]. The
strict regulation of C4.4A expression is clearly illustrated
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by immunohistochemical stainings of epithelial transition
zones such as the uterovaginal and anorectal junctions, where
C4.4A displays an all-or-nothing shift in its expression pat-
tern at the border between squamous and columnar epithelia
[12].
An early study comparing rat pancreatic adenocarcinoma
cell lines proposed a link between C4.4A and metastasis [16].
Prompted by this intriguing association, several subsequent
studies independently reported that high C4.4A expression
in solid cancer lesions of patients suffering from pulmonary
adenocarcinoma [17–20], esophageal squamous cell carci-
noma [21, 22], and colorectal adenocarcinoma [23] generally
correlates to poor patient survival. During a comprehensive
survey of a number of invasive and noninvasive skin lesions
[24], we observed that C4.4A was only upregulated in the
front of invasive lesions, and this occurred independently
of whether they were malignant (squamous cell carcinomas)
or benign (keratoacanthomas). In the normal skin, C4.4A
expression is predominantly linked to keratins (K) 1 and 10,
but, in the invasive lesions, it shifts to K5 and K14—which
is indicative of a lower differentiation state of the invading
keratinocytes [24]. Along the same lines, the deep invasive
regions of human esophageal squamous cell carcinomas
present a pronounced C4.4A expression [21]. Migrating ker-
atinocytes also express significant amounts of C4.4A during
reepithelization of incisional murine skin wounds [15].
Despite this clear impact as robust biomarkers for strati-
fied squamous cell differentiation and prognostic impact on
particularly pulmonary adenocarcinoma patient survival, the
functional role of C4.4A in maintaining epithelial integrity
and promoting invasion remains enigmatic. Mice deficient in
C4.4A expression by Lypd3 gene ablation have only modest
overt phenotypes [25]. To be able to supplement studies
on this genetic mouse model with a human counterpart,
we therefore characterize the expression of C4.4A in a
surrogate in vitro model of human skin produced by the
self-assembly approach of tissue engineering [26, 27]. The
development of the epidermis into a fully stratified four-layer
squamous epithelium, including the basal, spinous, granular,
and corneal layers, can be closely monitored as a function of
time in this human tissue-engineered skin substitute (TES)
[28, 29].
2. Materials and Methods
The institution’s committee for the protection of human
subjects approved the study. All procedures followed were in
accordance with the Helsinki Declaration of 1975.
2.1. Cell Culture. Fibroblasts were isolated from human skin
biopsies obtained from reductive breast surgery (21-year-
old) and foreskin (3-day-old). Keratinocytes were isolated
from foreskin, breast, and facelift surgeries (4-day-old, 61-
and 55-year-old, resp.). All biopsies were obtained after
informed consent was given. Fibroblasts and keratinocytes
were extracted, cultured, cryopreserved, and thawed as
described [30]. Fibroblasts were cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM; Invitrogen) with 10% fetal
calf serum (HyClone). Keratinocytes were grown on a feeder
layer of irradiated murine 3T3 fibroblasts as described [31]
and cultured in DMEM/Ham’s F12 medium (Invitrogen) in
a 3 : 1 proportion, supplemented with 24.3𝜇g/ml adenine
(Sigma-Aldrich, ON, Canada), 5% FetalClone II (HyClone),
5 𝜇g/ml insulin (Sigma-Aldrich), 0.4 𝜇g/ml hydrocortisone
(Calbiochem), 0.1 nM cholera toxin (Sigma-Aldrich), and
10 ng/ml epidermal growth factor (Austral Biologicals). Anti-
biotics (100 IU/ml penicillin G and 25 𝜇g/ml gentamicin [BD
Bioscience]) were added to both culture media. For immu-
nofluorescence, keratinocytes and 3T3 were grown on cov-
erslips (22 × 22mm; Fisher Scientific) in 6-well plates until
80%confluence.All cultureswere kept at 37∘C in a humidified
incubator containing 8% CO
2
, and the culture medium was
changed three times per week.
2.2. Production of Human Tissue-Engineered Skin. The
method of reconstruction of human skin by the self-assembly
approach of tissue engineering has been described in detail
elsewhere [32]. Briefly, human fibroblasts were cultured 28
days in medium containing 50 𝜇g/ml ascorbic acid, which
promotes the secretion of extracellular matrix, leading to the
organization of cells into manipulable tissue sheets. Two of
these sheets were stacked to make up the dermal portion of
the TES. After one week of culture, allowing the fusion of
the sheets, keratinocytes were seeded on top of these and
kept in submersion for another week. The process of epider-
mal differentiation of the keratinocytes was initiated by
raising the TES to the air-liquid (A/L) interface. Biopsies were
taken every day for the first 14 days of culture at the A/L
interface. Tissue samples were embedded in optimal cutting
temperature (OCT) compound, frozen in liquid nitrogen,
and stored at −80∘C until analysis.
2.3.WoundHealing inHumanTissue-Engineered Skin. At day
11 A/L, mature TES composed of newborn keratinocytes (4-
day-old) and adult fibroblasts (21-day-old) was wounded by a
6mm punch biopsy (Acuderm Inc.) as described previously
[33]. Migration of the keratinocytes for reepithelialization
of the wound was allowed by placing the wounded skin
on a third fibroblast sheet produced as described above.
The healing process was followed microscopically by biopsy
collection at different time points.
2.4. Immunofluorescence Stainings. Adult and newborn ker-
atinocytes in monolayer culture were grown on coverslips
(22 × 22mm; Fisher Scientific) in 6-well plates until they
proliferated to 80% confluence. Cells were rinsed in phos-
phate buffered saline (PBS), permeabilized in 99% methanol
at −20∘C for 10min, and conserved in PBS. Frozen tissue
embedded in OCT was sectioned at 5𝜇m, fixed in acetone
at −20∘C for 10min, and rinsed in PBS. For immunofluores-
cence staining, slides or coverslips were incubated with pri-
mary antibodies (25 𝜇l/section) for 45min at room temper-
ature and with Alexa Fluor dye-conjugated secondary anti-
bodies for 30min in darkness (25𝜇l/section). For double
immunofluorescence, the two primary antibodieswere added
simultaneously to the sections and detected with species-
specific anti-IgG antibodies. Cell nuclei were visualized
with Hoechst 33258 (Sigma) and the sections mounted in
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Figure 1: C4.4A in monolayer culture of human keratinocytes. (a, b) C4.4A expression in cultured human keratinocytes. Confinement of
C4.4A to points of cell-cell contact is emphasized by arrows. (c) Colocalization of C4.4A (green) with the adherens junction protein 𝛽-
catenin (red) in TES at day 28 of culture at the A/L interface. Corresponding phase contrast pictures are depicted in panels (a󸀠), (b󸀠), and
(c󸀠), respectively. Cell nuclei are stained with Hoechst (blue). Note that murine 3T3 fibroblasts were devoid of C4.4A expression (arrowhead).
Open arrows point toward less differentiated keratinocytes at the periphery of the colony, which are not labeled for C4.4A. A/L, air-liquid; d,
day; TES, tissue-engineered skin. Scale bar: (a) and (a󸀠), 50 𝜇m; (b), (b󸀠), (c), and (c󸀠), 25 𝜇m.
PBS/glycerol/gelatin (pH 7.6). The primary antibodies used
in this study were rabbit polyclonal antibodies (pAbs) raised
against a recombinant secreted version of human C4.4A,
Haldisin [13, 15, 34] and K14 peptide [35], and mouse
monoclonal antibodies recognizing domains I + II of C4.4A
[21], K10 clone RKSE60 (Cedarlane Laboratories), laminin-5
𝛾2 (Millipore),𝛽-catenin (SantaCruz), and anti-𝛼3 subunit of
integrin clone HB-8530 (VM2). Goat anti-rabbit IgG coupled
to Alexa 488 and anti-mouse IgG coupled to Alexa 594
(Molecular Probes) were used as secondary antibodies, yield-
ing green and red fluorescence signals, respectively. Negative
controls consisted in omitting the primary antibodies in the
staining procedure. Fluorescence and phase contrast images
were recorded using a Zeiss Axio Imager M2 microscope
(Carl Zeiss Canada Ltd.).
3. Results
3.1. C4.4A Expression in Keratinocytes Grown in Monolayer.
To check the C4.4A expression pattern in human ker-
atinocytes before their seeding on fibroblast sheets for sub-
sequent squamous differentiation within TES, keratinocytes
grown in monolayer were immunolabeled with our anti-
C4.4A pAb [15]. The results showed that some keratinocytes
in monolayer cultures highly expressed C4.4A at cell-cell
borders (Figures 1(a)-1(b), arrows), while the murine 3T3
fibroblasts, used as a feeder layer in the culture, were devoid
of reactivity (Figure 1(a), arrowhead). It is interesting to
note that some of the less differentiated keratinocytes at the
periphery of isolated colonies were not labeled (Figure 1(a),
open arrows). Although C4.4A in general was found at the
cell membrane, it was nonetheless predominantly confined
to those regions forming cell-cell contact points. As evident
from double immunofluorescence staining of TES at day 28
A/L, C4.4A colocalized with the adherens junction protein
𝛽-catenin (Figure 1(c)). Donor age did not modify the C4.4A
expression pattern in keratinocytes.
3.2. C4.4A Expression in Human Tissue-Engineered Skin.
TESs were produced by the self-assembly method of tissue
engineering and showed expected characteristics, such as the
presence of dermal component covered by an epidermis with
the absence of glands and hair follicles (Figures 2 and 3)
[27, 32, 36]. To follow the development of a fully stratified
squamous epithelium and to determine at which point of
the epidermal genesis C4.4A expression is initiated in TESs,
biopsies were collected every day after raising the TES to
the A/L interface, until day 11, and biopsy sections were
immunostained. C4.4A was already present at day 1 A/L
(Figure 2(a)) and its expression was maintained throughout
the development of the fully stratified epidermis (Figures
2(b)–2(g)). At day 2 of culture at the A/L interface, the
staining was confined to suprabasal cells, leaving the stratum
basale devoid of C4.4A. Of note, the C4.4A expression was
almost lost in the higher suprabasal cells around day 7 of
culture at theA/L interface (Figure 2(e), asterisk).The stratum
corneum was also negative for C4.4A, as well as fibroblasts in
the underlying dermis. Double immunofluorescence staining
for K10, a differentiation marker for keratinocytes present in
the suprabasal layers of the epidermis [37], showed that both
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Figure 2: C4.4A in the development of human tissue-engineered skin. (a–g) Expression of C4.4.A (green) in TES at days 1 (a), 2 (b), 3 (c), 4
(d), 7 (e), 9 (f), and 11 (g, h) of culture at the A/L interface. (a󸀠), (b󸀠), (c󸀠), (d󸀠), (e󸀠), (f󸀠), and (g󸀠): Phase contrast images corresponding to panels
(a), (b), (c), (d), (e), (f), and (g) respectively. (h) Negative control (omission of the primary antibody). Cell nuclei are stained with Hoechst
(blue). A/L, air-liquid; d, day; sb, stratum basale; ss, stratum spinosum; sg, stratum granulosum; sc, stratum corneum; TES, tissue-engineered
skin. Scale bar: 25 𝜇m.
C4.4A and K10 were absent in the basal layer but expressed
in the spinous layer (Figures 3(a)-3(b)). As expected, the anti-
K14 reacted with basal keratinocytes that were negative for
C4.4A (Figure 3(d)). Given that C4.4A is absent in stratum
basale, there was no contact with the laminin-5-expressing
basement membrane (Figure 3(f)). The organization of the
TES thus recapitulates the anatomical stratification of C4.4A
expression we find in, for example, the esophageal epithelium
[21]. As illustrated in Figures 3(g)–3(i), amultilayered stratum
granulosum is also formed from day 6 to day 8 after exposure
to the A/L interface, and this is accompanied by expression
of Haldisin—the other epithelial differentiation biomarker
belonging to the LU protein domain family. Keratinocytes
from three different donors (4-day-old, 55- and 61-year-old)
were used to produce TESs without affecting the C4.4A and
Haldisin expression and localization.
3.3. C4.4A Expression in a Human Tissue-Engineered Wound
HealingModel. Wenext evaluated the expression of C4.4A in
a wound healing model produced with human TES [33]. The
distribution of the integrin 𝛼3𝛽1, which is highly expressed in
basal keratinocytes and which undergoes change in relative
intensity at the tip of the migrating epithelial tongue during
wound healing [38], was also evaluated. Upon wounding by
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Figure 3: C4.4A expression in relation to epidermal differentiation markers. (a) Expression of C4.4A (green) and K10 (red) in TES at day
10 of culture at the A/L interface. K10 labeling is also shown separately in panel (b). (d) Expression of C4.4A (red) and K14 (green) in TES
at day 11 of culture at the A/L interface. (f) Expression of C4.4A (green) and the basement membrane marker laminin-5 (red) in TES at day
11 of culture at the A/L interface. (g–i) Expression of C4.4A (red) and Haldisin (green) in TES at days 6–8 of culture at the A/L interface. (c
and e) Phase contrast images corresponding to panels (b) and (d), respectively. Cell nuclei are stained with Hoechst (blue). The difference in
K10 and K14 expression in the basal layer is emphasized by asterisks in panels (a), (b), and (d). The localization of the basement membrane,
separating the fibroblast sheets of the dermal portion of the TES from the keratinocytes of the epidermal compartment is stressed by a dotted
line in panels (a), (b), (c), (e), (g), (h), and (i). A/L, air-liquid; K, keratin; sb, stratum basale; ss, stratum spinosum; sg, stratum granulosum; sc,
stratum corneum; TES, tissue-engineered skin. Scale bar = 50𝜇m.
a punch biopsy, keratinocytes at the margin of the wound
start migrating on the extra fibroblast sheet upon which the
wounded TES is placed, to close the wound. As illustrated in
Figures 4(a) and 4(b), C4.4A was expressed suprabasally in
the migrating epithelial tongue, and the labeling was negative
in the basal keratinocytes that highly expressed the 𝛼3 sub-
unit of integrin (Figure 4(b)). Interestingly, some foremost
suprabasal keratinocytes at the tip of the migrating epithe-
lial tongue were devoid of C4.4A (Figures 4(a) and 4(b),
arrows), in agreement with our previous study of murine
incisional skin wounds [15]. These C4.4A-negative sup-
rabasal cells expressed the 𝛼3 subunit of integrin at the same
level as basal cells (Figure 4(b), arrow).
4. Discussion
Given the expression pattern of the multidomain LU protein
C4.4A in squamous epithelium, we have taken advantage of a
surrogate model of human skin to investigate the expression
kinetics of this protein in the genesis of a fully stratified
epidermis. In line with previous observations in human skin
[15], our results show that C4.4A is expressed in the spinous
cells, of which one layer is already present at day 1 of culture
at the A/L interface (Figure 2(a)). Over the next days of
incubation, epidermal cells feed the development of a highly
organized, stratified epithelium comprising several layers. At
day 7, Haldisin expression was predominant in the upper
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Figure 4: C4.4A in tissue-engineered wound healing model. (a-b) Tissue section of a human TES stained for C4.4A (green in (a) and red in
(b)) and the 𝛼3 subunit of integrin (green in (b)) two days after the creation of a wound. Cell nuclei are stained with Hoechst (blue). Note
that the foremost suprabasal keratinocytes of the migrating front that highly express the 𝛼3 subunit of integrin are devoid of C4.4A (arrows).
(a󸀠) Phase contrast image corresponding to panel (a). 𝛼3, 𝛼3 subunit of integrin; AW, after wound; TES, tissue-engineered skin. Scale bar =
50 𝜇m.
cells of the granular layer of TESs in accordance with its
expression pattern in mouse and human skin [13]. From
day 1 to day 4, C4.4A expression exhibits a gradually more
distinctmembrane localization.This progression is paralleled
in the corresponding in vivo process as studied in mouse
embryogenesis, where C4.4A appears diffusely at embryonic
day 14.5 (E14.5), when the spinous layer of the fetal back
skin is about to develop in the approximately three-layered
epithelium [39]. One day later, at E15.5, C4.4A presents
with a strong membrane association [12]. Finally, the results
obtained with the human tissue-engineered wound healing
model, where the foremostmigrating suprabasal keratinocyte
is negative forC4.4A (Figure 4), complywith the in vivo situa-
tion as seen in murine incisional wounding [15].
It is well established that the basal-to-suprabasal switch
taking place upon commitment to terminal differentiation
of the epidermis is accompanied by a change in keratin
expression from K5/14 in the basal cells to K1/10 suprabasally
[40, 41]. As evident from the presented double immunoflu-
orescence stainings, and inherently linked to the absence
of C4.4A in the basal layer, the onset of C4.4A expression
coincides with that of K10, indicating that C4.4A likewise
could be a marker for this basal-to-spinous switch. In murine
embryogenesis, C4.4A expression is also induced at the
same time as K1/10 in the squamous epithelium of the nasal
cavity and the vibrissal follicles and even a little earlier in
the back and paw skin [12, 42, 43]. Furthermore, C4.4A
has been reported to be transcriptionally regulated by the
CCAAT/enhancer binding protein 𝛽 [44], which can be
induced by Notch, one of the main signals governing the
basal-to-suprabasal switch [40].
In accordance with earlier studies, our observations sup-
port a role of C4.4A in early squamous differentiation.
First, C4.4A is anatomically primarily localized to squamous
epithelium, being absent in columnar epithelium [12, 21]. Sec-
ond, treatment of murine skin with phorbol 12-myristate 13-
acetate, which can commit cells to terminal cell division and
ultimately squamous differentiation, entails an upregulation
of C4.4A, restricted to the suprabasal, and not the basal, kera-
tinocytes [15]. Third, the earliest appearance of C4.4A in
embryogenic development of the esophagus occurs at E15.5
[12], corresponding to the initiation of esophageal trans-
differentiation from a columnar to a stratified squamous
epithelium [45]. Finally, C4.4A is found very early in the
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progression to malignant squamous cell carcinoma of the
lung. While normal bronchial epithelium is devoid of C4.4A,
it is, surprisingly, expressed in basal cell hyperplasia [19],
which is a reactive change preceding the conversion into
bronchial squamous metaplasia [46, 47], yet another process
of transdifferentiation.
The functional consequences of this link to the squa-
mous phenotype are, however, still unclear. Circumstantial
evidence promotes the hypothesis of C4.4A being involved
in cell-cell adhesion, which is rendered probable by the teth-
ering of C4.4A to the cell membrane via a GPI-anchor [15].
The expression pattern of C4.4A is furthermore reminiscent
to that of the well-characterized cell adhesion molecules E-
cadherin [21] and 𝛽-catenin (Figure 1(c)). Our observations
in monolayer culture of keratinocytes also fit this picture,
with a clear membrane localization of C4.4A at cell-cell
interaction points, suggesting a role of C4.4A in, for example,
adherens junctions. In addition, the carbohydrate-binding
lectin galectin-3, which has been implicated in cell-cell inter-
actions and cell adhesion, has been identified as a ligand for
C4.4A [48]. It is tempting to speculate that the abundant N-
and O-linked glycosylation present in C4.4A [15] is targeted
by the carbohydrate recognition domain of this lectin, with
ensuing cross-linking of two neighboring cells [49].
It has already been clearly established that the self-
assembly method of tissue engineering produces a skin
substitute that to a very high degree mimics the anatomy of
human skin, with the formation of the four characteristic epi-
dermal cell layers that express well-established keratinocyte
differentiation markers and a basement membrane at the
dermal-epidermal junction [26]. The present results lend
additional support to the applicability of this in vitro model
for reporting on the corresponding in vivo situation, as
illustrated by the tight regulation of the expression of C4.4A.
A further strength of this substitute is that it is comprised
of solely human components, which presents advantages as
compared to the use of mouse models, given that it is not
always biologically relevant to extrapolate results obtained in
a murine system to the human counterpart. In the case of
skin, there is an obvious species difference in the thickness
of the epidermis, which might influence the mechanisms
involved in epidermal development and wound healing.
5. Conclusions
In conclusion, we have demonstrated the potential utility of
an in vitro surrogate model of human skin for performing
functional studies on C4.4A and Haldisin, which ultimately
could delineate the unknown biological role of these proteins.
Such investigationsmight provide a framework for explaining
our previous interesting finding of the high impact of C4.4A
in the prognosis of patients with pulmonary adenocarcinoma
[17, 20].
Abbreviations
A/L: Air/liquid
DMEM: Dulbecco’s modified Eagle’s medium
E: Embryonic day
GPI: Glycosyl-phosphatidyl-inositol
K: Keratin
LU: Ly6/uPAR
OCT: Optimal cutting temperature
pAbs: Polyclonal antibodies
PBS: Phosphate buffer saline
TES: Tissue-engineered skin
uPAR: Urokinase-type plasminogen activator receptor.
Additional Points
Major Take-Home Points. (i) C4.4A is located at cell-cell
contact points between the more differentiated keratinocytes
in monolayer culture. (ii) C4.4A expression emerges with
the formation of a stratum spinosum layer in an in vitro
developing human tissue-engineered skin model. (iii) After
the creation of a wound, this tissue-engineered skin model
recapitulates the dynamic expression of C4.4A as seen in
themigrating suprabasalmurine keratinocytes duringwound
healing. (iv) Tissue-engineered skin provides an optimal and
convenient in vitro model for functional studies of C4.4A in
human squamous epithelia.
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